Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MARS1 | P56192 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29873645 | 0.89 | MAPT (0.45) | TP53SMN1; SMN2MARS1L3MBTL1MAPT | |
| SCHEMBL15577159 | 0.83 | MAPT (0.48) | TP53SMN1; SMN2L3MBTL1MAPTCNR1 | |
| SCHEMBL15578585 | 0.81 | SRD5A2 (0.41) | SMN1; SMN2MARS1MAPT | |
| SCHEMBL15577134 | 0.81 | ALDH1A1 (0.51) | TP53SMN1; SMN2MARS1L3MBTL1MAPT | |
| SCHEMBL2327827 | 0.79 | KMT2A (0.47) | — | |
| SCHEMBL23367219 | 0.77 | RPA1 (0.40) | — | |
| SCHEMBL1752087 | 0.76 | P2RX7 (0.53) | — | |
| SCHEMBL27656182 | 0.75 | MARS1 (0.45) | TP53SMN1; SMN2MARS1L3MBTL1MAPT | |
| SCHEMBL11378183 | 0.75 | ADAMTS7 (0.45) | TP53SMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL18910106 | 0.75 | HDAC1 (0.39) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| EP-4058446-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021094434-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021094434-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| EP-3822265-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer AG (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-3822265-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer AG (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-2895478-B1 | TRIAZOLE CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-10-19 | — | — | EP | disclosed |
| US-9416127-B2 | Triazole carboxamides and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2016-08-16 | — | — | US | disclosed |
| EP-2895478-A1 | TRIAZOLE CARBOXAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-07-22 | — | — | EP | disclosed |
| US-20150191458-A1 | TRIAZOLE CARBOXAMIDES AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2015-07-09 | — | — | US | disclosed |
| CN-104603129-A | Triazole carboxamide derivatives | HOFFMANN LA ROCHE | 2015-05-06 | — | — | CN | disclosed |
| WO-2014041106-A1 | TRIAZOLE CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191458-A1 | TRIAZOLE CARBOXAMIDES AND USES THEREOF | TAAR1, HCRTR1, TAAR5 | TP53 4854/4885SMN1; SMN2 2630/4885MARS1 2979/4885 |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAMTS1 | TP53 4354/4885SMN1; SMN2 3772/4885MARS1 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.